Clinical Trials Sponsored by Valneva Austria GmbH

Total 94 results

Valneva Austria GmbH

Recruiting

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Zika | Zika Virus Infection

United States
Valneva Austria GmbH

Completed

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 (COV-COMPARE)

SARS-CoV-2 Virus Infection

United Kingdom
Valneva Austria GmbH

Active, not recruiting

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)

Chikungunya Virus Infection

United States
Valneva Austria GmbH

Completed

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

Chikungunya

United States
Valneva Austria GmbH

Completed

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers

Healthy

Austria, Germany
Valneva Austria GmbH

Completed

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Not yet recruiting

A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)

Chikungunya Virus Infection
Valneva Austria GmbH

Completed

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

Chikungunya Virus Infection

United States
Valneva Austria GmbH

Completed

VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

SARS-CoV-2 Infection

New Zealand, Netherlands
Valneva Austria GmbH

Withdrawn

COVID-19 Paediatric VLA2001-321 Study

SARS-CoV-2 Infection
Valneva Austria GmbH

Completed

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Japanese Encephalitis

Australia, United States, Germany
Valneva Austria GmbH

Completed

Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43

Pseudomonas Aeruginosa Infection

Spain, Germany, Belgium, Austria, Czech Republic, Hungary
Valneva Austria GmbH

Completed

Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country

Japanese Encephalitis

Philippines
Valneva Austria GmbH

Completed

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Austria, Germany
Valneva Austria GmbH

Completed

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Japanese Encephalitis
Valneva Austria GmbH

Completed

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Virological Response Study of the HCV Vaccine IC41

Chronic Hepatitis C

Germany, Poland, Romania
Valneva Austria GmbH

Recruiting

A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years

Chikungunya Virus Infection

Dominican Republic, Honduras
Valneva Austria GmbH

Completed

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

SARS-CoV-2 Virus Infection

New Zealand
Valneva Austria GmbH

Completed

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

Chikungunya Virus Infection

United States
Valneva Austria GmbH

Completed

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Encephalitis

Philippines
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden
Valneva Austria GmbH

Completed

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

Clostridium Difficile

Germany, United States
Valneva Austria GmbH

Completed

Safety Surveillance After Immunization With IXIARO

Japanese Encephalitis

United States
Valneva Austria GmbH

Completed

An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84

Clostridium Difficile Infection

Austria, Hungary
Valneva Austria GmbH

Withdrawn

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

Japanese Encephalitis

United Kingdom
Valneva Austria GmbH

Completed

Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine

Chronic Hepatitis C
Valneva Austria GmbH

Completed

Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients

Pneumonia, Ventilator-Associated

Austria
Pfizer
Valneva Austria GmbH

Completed

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Lyme Borreliosis, Nervous System

Belgium, United States
Valneva Austria GmbH
PATH

Completed

Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47

Pneumococcal Infections

Germany
Pfizer
Valneva Austria GmbH

Active, not recruiting

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Lyme Borreliosis

United States
Pfizer
Valneva Austria GmbH

Active, not recruiting

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) (VALOR)

Lyme Disease

United States, Finland, Canada, Poland, Sweden, Germany, Netherlands
Pfizer
Valneva Austria GmbH

Completed

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

Lyme Borreliosis

United States
Butantan Institute
Valneva Austria GmbH

Active, not recruiting

A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

Chikungunya

Brazil
Valneva Austria GmbH
Emergent BioSolutions

Completed

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

Zika Virus Infection | Zika Virus

United States
Medical University of Vienna
Valneva Austria GmbH

Unknown

Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.

Japanese Encephalitis Vaccine

Austria
Valneva Austria GmbH
Johns Hopkins University; Naval Medical Research Center

Completed

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

Diarrhea | Enterotoxigenic Escherichia Coli Infection

United States
Valneva Austria GmbH
National Institute for Health Research, United Kingdom

Completed

Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects

SARS-CoV-2 Virus Infection

United Kingdom
Austrian Breast & Colorectal Cancer Study Group
Pharmacia Austria GmbH

Completed

Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane

Breast Cancer

Austria
Austrian Breast & Colorectal Cancer Study Group
Merck Gesellschaft mbH, Austria

Terminated

A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis (G-LUCAS)

Colorectal Cancer | Steatohepatitis

Austria
Austrian Breast & Colorectal Cancer Study Group
Hoffmann-La Roche; Merck Gesellschaft mbH, Austria

Completed

Preoperative Chemoradiation With Capecitabine and Cetuximab

Rectal Cancer

Austria
Synthes GmbH
Synthes Australia Pty Ltd

Withdrawn

Observational Patient Registry of the Dynamic Locking Screws (DLS)

Proximal or Diaphyseal Humerus Fracture | Diaphyseal or Distal Femur Fracture | Diaphyseal, Distal or Proximal Tibia Fracture

Australia
Mathias Maleczek
Medical University of Vienna; Philips Austria GmbH

Completed

Advisory Lead ARDS Respirator Management (ALARM)

ARDS, Human

Austria

3

Subscribe